The stock price of Ideaya Biosciences Inc (NASDAQ: IDYA) has surged by 7.09% when compared to previous closing price of $21.45, but the company has seen a 8.76% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-27 that SOUTH SAN FRANCISCO, Calif., June 27, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 26, 2025, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 95,600 shares of the Company’s common stock to a newly hired employee.
Is It Worth Investing in Ideaya Biosciences Inc (NASDAQ: IDYA) Right Now?
Moreover, the 36-month beta value for IDYA is 0.08. Analysts have varying opinions on the stock, with 11 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IDYA is 78.78M and currently, short sellers hold a 14.40% of that float. On July 10, 2025, IDYA’s average trading volume was 1.34M shares.
IDYA’s Market Performance
IDYA stock saw an increase of 8.76% in the past week, with a monthly gain of 5.71% and a quarterly increase of 51.72%. The volatility ratio for the week is 4.28%, and the volatility levels for the last 30 days are 4.46% for Ideaya Biosciences Inc (IDYA). The simple moving average for the past 20 days is 5.02% for IDYA’s stock, with a -1.61% simple moving average for the past 200 days.
Analysts’ Opinion of IDYA
Many brokerage firms have already submitted their reports for IDYA stocks, with Wells Fargo repeating the rating for IDYA by listing it as a “Overweight.” The predicted price for IDYA in the upcoming period, according to Wells Fargo is $44 based on the research report published on June 26, 2025 of the current year 2025.
Stephens, on the other hand, stated in their research note that they expect to see IDYA reach a price target of $51. The rating they have provided for IDYA stocks is “Overweight” according to the report published on November 18th, 2024.
Leerink Partners gave a rating of “Market Perform” to IDYA, setting the target price at $27 in the report published on November 05th of the previous year.
IDYA Trading at 12.61% from the 50-Day Moving Average
After a stumble in the market that brought IDYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.29% of loss for the given period.
Stock Fundamentals for IDYA
Current profitability levels for the company are sitting at:
- -51.48 for the present operating margin
- 0.75 for the gross margin
The net margin for Ideaya Biosciences Inc stands at -43.76. The total capital return value is set at -0.34. Equity return is now at value -31.34, with -29.78 for asset returns.
Based on Ideaya Biosciences Inc (IDYA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -10.17.
Currently, EBITDA for the company is -326.98 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 272.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.92.
Conclusion
To wrap up, the performance of Ideaya Biosciences Inc (IDYA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
